| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 04/20/2000 | WO2000021995A1 Treatment of inflammatory disease |
| 04/20/2000 | WO2000021986A2 Matrix-remodeling genes |
| 04/20/2000 | WO2000021978A2 Laminin 5, 13 and 14 and uses thereof |
| 04/20/2000 | WO2000021976A1 Bone morphogenic protein-induced genes and polypeptides, and their use in diagnostic and therapeutic methods |
| 04/20/2000 | WO2000021575A2 Calpain inhibitors and their applications |
| 04/20/2000 | WO2000021559A2 Blocking factor b to treat complement-mediated immune disease |
| 04/20/2000 | WO2000021557A1 Delta 6 fatty acid desaturase |
| 04/20/2000 | WO2000021553A2 Method of regulating smn gene expression |
| 04/20/2000 | WO2000021544A1 Ups (undecaprenyl diphosphate synthase) |
| 04/20/2000 | WO2000021370A1 Oligonucleotide delivery systems for camptothecins |
| 04/20/2000 | WO2000006775A9 Exon deletion antisense drug design and therapy |
| 04/20/2000 | WO2000005343A3 Cell expansion system for use in neural transplantation |
| 04/20/2000 | WO2000003685A3 Nitrilase homologs |
| 04/20/2000 | WO2000003004A3 Presenilin 2 specific ribozyme |
| 04/20/2000 | WO2000001440A3 Methods for treating neurological injuries and disorders |
| 04/20/2000 | WO1999066065A3 Proteasomal activity |
| 04/20/2000 | WO1999066037A3 Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
| 04/20/2000 | WO1999060986A3 Apoptosis modulators that interact with the huntington's disease gene |
| 04/20/2000 | WO1999057266A3 Immunosuppression by blocking t cell co-stimulation signal 2 (b7/cd28 interaction) |
| 04/20/2000 | WO1999054463A3 Human k+ ion channel and therapeutic applications thereof |
| 04/20/2000 | WO1999053062A3 Isolated sh3 genes associated with myeloproliferative disorders and leukemia, and uses thereof |
| 04/20/2000 | DE19848017A1 Episomally replicating vectors, useful in gene therapy, contain origins of replication and scaffold-matrix attached region sequences but no viral coding sequences |
| 04/20/2000 | DE19847064A1 Mutant AMPA-type glutamate receptor, useful for identifying receptor agonists and antagonists, lacks the desensitizing properties of the wild-type receptor |
| 04/20/2000 | CA2347653A1 Novel cell signaling polypeptides and nucleic acids |
| 04/20/2000 | CA2347121A1 (mbp1) polypeptides capable of interacting with oncogenic mutants of the p53 protein |
| 04/20/2000 | CA2347091A1 Method and apparatus for direct in vivo gene transfer by electrotransfecection |
| 04/20/2000 | CA2346776A1 Non-desensitizing ampa-receptors |
| 04/20/2000 | CA2346713A1 Neisseria genomic sequences and methods of their use |
| 04/20/2000 | CA2346155A1 Enzymatic synthesis of ssdna |
| 04/20/2000 | CA2346006A1 Delta 6 fatty acid desaturase |
| 04/20/2000 | CA2345900A1 Selectively replicating viral vectors |
| 04/20/2000 | CA2345885A1 Bone morphogenic protein-induced genes and polypeptides, and their use in diagnostic and therapeutic methods |
| 04/20/2000 | CA2345211A1 Recombinant e1a deleted adenoviral vectors |
| 04/20/2000 | CA2344711A1 Expression and secretion of icil-1 receptor antagonist type ii |
| 04/20/2000 | CA2314004A1 Matrix-remodeling genes |
| 04/19/2000 | EP0993468A1 Compositions and methods for activating genes of interest |
| 04/19/2000 | EP0993318A1 Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo |
| 04/19/2000 | EP0993305A2 Composition for enhanced uptake of polar drugs from mucosal surfaces |
| 04/19/2000 | EP0586520B1 Backbone modified oligonucleotide analogs |
| 04/19/2000 | CN1251047A Process for stimulating neural regeneration |
| 04/19/2000 | CN1251042A Identification of broadly reactive DR restricted epitopes |
| 04/18/2000 | US6051691 Amino acid sequence of protein; for screening bactericides and bacteristats especially targeted to streptococci |
| 04/18/2000 | US6051688 Amino acid sequence for polypeptide of at least 6 contiguous amino acids; for diagnosis and treatment of nervous system disorders; anticonvulsants; antiischemic/antihypoxic agents; antiepileptic agents; alzheimer's/parkinson's diseases |
| 04/18/2000 | US6051430 Vectors and methods for providing cells with additional nucleic acid material integrated in the genome of said cells |
| 04/18/2000 | US6051429 Peptide-enhanced cationic lipid transfections |
| 04/18/2000 | US6051428 Transducing tumor cells with herpes simplex virus amplicon containing gene coding for cytokines, chemokines, cellular adhesion molecules, or costimulatory molecules which activate b or t-cells for transient expression of the protein |
| 04/18/2000 | US6051427 Retroviral packaging plasmid including retroviral helper dna lacking native enhancer and/or promoter of the viral 5' long terminal repeat, the psi function sequence and the 3' long terminal repeat, but encodes foreign regulatory sequences |
| 04/18/2000 | US6051402 A nucleic acid encoding an anti-sickling beta-globin protein; gene therapy for sickle cell |
| 04/18/2000 | US6051400 An expression system comprising of a polynucleotide encoding a protein; therapy and diagnosis of kidney diseases, cardiovascular disorders, strokes, alzheimer's disease; anticarcinogenic agents and antiinflammatory agents |
| 04/18/2000 | US6051396 Method for producing retinoblastoma gene protein products |
| 04/18/2000 | US6051232 Comprising allogenic chimeric major histocompatibility complex class i milecule; to induce tolerance to donor grafts when administered to the recipient at time of transplantation |
| 04/18/2000 | US6051222 Cancer diagnosis; genetic engineering |
| 04/18/2000 | US6051221 BRK protein tyrosine kinase and encoding nucleic acid |
| 04/18/2000 | US6051218 Administering cell expressing interleukin-3 |
| 04/18/2000 | CA2092195C Retroviral packaging cell line |
| 04/17/2000 | CA2284849A1 Episomally replicating vector, its preparation and use |
| 04/13/2000 | WO2000020645A1 ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-α (TNF-α) EXPRESSION |
| 04/13/2000 | WO2000020635A1 ANTISENSE MODULATION OF INTEGRIN α4 EXPRESSION |
| 04/13/2000 | WO2000020621A1 Extracellular novel rage binding protein (en-rage) and uses thereof |
| 04/13/2000 | WO2000020619A2 Secreted renilla luciferase |
| 04/13/2000 | WO2000020617A1 Intercellular propagation of recombinant dna |
| 04/13/2000 | WO2000020608A1 Method of treating prostate cancer with an adenovirus expression vector encoding a prodrug enzyme |
| 04/13/2000 | WO2000020587A2 Cancer associated antigens and uses therefor |
| 04/13/2000 | WO2000020582A2 Gene replacement therapy for muscular dystrophy |
| 04/13/2000 | WO2000020579A1 Spliced form of erbb-2/neu oncogene |
| 04/13/2000 | WO2000020578A1 A method of modulating cell survival and reagents useful for same |
| 04/13/2000 | WO2000020572A2 Tissue binding peptides, identification, production and utilization thereof |
| 04/13/2000 | WO2000020560A1 Engraftable neural progenitor and stem cells for brain tumor therapy |
| 04/13/2000 | WO2000020457A1 Peptides related to an igf-ii-r epitope, polynucleotides encoding the peptides, and their use in immunomodulation |
| 04/13/2000 | WO2000020450A2 Calcium channel alpha-2/delta gene |
| 04/13/2000 | WO2000020448A2 Nlk1 -interacting proteins |
| 04/13/2000 | WO2000020435A1 ANTISENSE MODULATION OF EXPRESSION OF TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED FACTORS (TRAFs) |
| 04/13/2000 | WO2000020434A1 Cadherin-like asymmetry protein-1, and methods for its use |
| 04/13/2000 | WO2000020433A1 Cytotoxic agents for the selective killing of lymphoma and leukemia cells and methods of use thereof |
| 04/13/2000 | WO2000020432A1 Antisense modulation of bcl-x expression |
| 04/13/2000 | WO2000020041A2 Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent |
| 04/13/2000 | WO2000020040A1 Controlling gene expression in living cells |
| 04/13/2000 | WO2000020038A1 Method of treating prostate cancer with an adenovirus vector |
| 04/13/2000 | WO2000020037A1 A novel component in the hedgehog signalling pathway |
| 04/13/2000 | WO2000020029A1 Genes differentially expressed in cancer cells to design cancer vaccines |
| 04/13/2000 | WO2000020026A2 Compositions and methods for inhibiting angiogenesis |
| 04/13/2000 | WO2000019978A2 Compositions and methods for enhancing receptor-mediated cellular internalization |
| 04/13/2000 | WO2000019883A2 Compositions and methods of disease diagnosis and therapy |
| 04/13/2000 | WO2000001813A3 Peptide inhibitors of androgen-independent activation of androgen receptor |
| 04/13/2000 | WO2000000603A3 Modularly constructed rna molecules having two sequence region types |
| 04/13/2000 | WO2000000224A3 Method for transporting a molecular substance in predetermined areas of eucaryotic cells |
| 04/13/2000 | WO1999064565A9 Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells |
| 04/13/2000 | WO1999063094A3 Nucleotide and protein sequences of gpr1 and methods based thereon |
| 04/13/2000 | WO1999058151A3 Synthetic polyaminoacid complexes for delivery of nucleic acids to target cells |
| 04/13/2000 | WO1999055345A9 Combination viral-based and gene-based therapy of tumors |
| 04/13/2000 | DE19845420A1 Interzelluläre Ausbreitung rekombinanter DNA Intercellular propagation of recombinant DNA |
| 04/13/2000 | CA2347120A1 Nlk1 -interacting proteins |
| 04/13/2000 | CA2346765A1 Compositions and methods of disease diagnosis and therapy |
| 04/13/2000 | CA2346217A1 Extracellular novel rage binding protein (en-rage) and uses thereof |
| 04/13/2000 | CA2345881A1 Bone marrow-derived serum proteins |
| 04/13/2000 | CA2345477A1 Peptides related to an igf-ii-r epitope, polynucleotides encoding the peptides, and their use in immunomodulation |
| 04/13/2000 | CA2345440A1 Genes differentially expressed in cancer cells to design cancer vaccines |
| 04/13/2000 | CA2345408A1 Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent |
| 04/13/2000 | CA2345214A1 Tissue binding peptides, identification, production and utilization thereof |
| 04/13/2000 | CA2345209A1 Antisense modulation of integrin .alpha.4 expression |